• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$6.28 $0.20 (3.29%)

REAL-TIME: Last trade at

Protalix BioTherapeutics, Inc.

AMEX:PLX

Jump to this page for:

Related Resources

Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR

5/7/2012 by Nasdaq

Why Protalix BioTherapeutics Shares Soared

5/2/2012 by DailyFinance

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May [UPDATE]

5/2/2012 by Minyanville

US Stocks Edge Lower On Weak Private-Sector Hiring

5/2/2012 by Smart Money

This Biotech Needs to Strike Fast

5/2/2012 by DailyFinance

US Stocks Trade Lower Late On Concerns Over Hiring, Europe

5/2/2012 by Smart Money

CORRECT: FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

5/1/2012 by Smart Money

UPDATE: FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

5/1/2012 by Smart Money

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May

4/30/2012 by Minyanville

The Big Bet on Protalix

4/30/2012 by DailyFinance

iBio Incorporated: Speculative Long Term Investment With Short Term Catalyst

4/9/2012 by Trefis

iBio Incorporated: Speculative Long Term Investment With Short Term Catalyst

4/9/2012 by Trefis

Pharmas Turn a Healthy Profit by Treating Rare Diseases

2/29/2012 by DailyFinance

Protalix BioTherapeutics Shares Plunged: What You Need to Know

2/16/2012 by DailyFinance

Company News for December 7, 2011 - Corporate Summary

12/7/2011 by Nasdaq

3 Stocks to Get on Your Watchlist

12/7/2011 by DailyFinance

As the Biotech Saying Goes...

12/7/2011 by DailyFinance

Protalix BioTherapeutics Shares Got Crushed: What You Need to Know

12/6/2011 by DailyFinance

Regeneron Wins FDA Approval for Eye Drug: 3 Companies Up For Approval

12/3/2011 by Nasdaq

Biotech: Top 3 Analyst Picks

4/7/2011 by Seeking Alpha

14 Small Caps With 2 or More Analyst Downgrades in March

4/4/2011 by Seeking Alpha

5 Stocks Near Lows Seeing Significant Short Covering

3/23/2011 by Seeking Alpha

Top 30 Most Undervalued, Underperforming Stocks

3/1/2011 by Seeking Alpha

Niche Opportunity May Be Slipping From Protalix's Grasp

3/1/2011 by Seeking Alpha

22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12

2/28/2011 by Seeking Alpha

The Prospects for Protalix Still Look Pretty Good

2/28/2011 by Seeking Alpha

What's Next for Protalix BioTherapeutics Shares Fall After FDA CRL?

2/27/2011 by Seeking Alpha

Protalix: FDA Requests More Information On Gaucher's Drug

2/25/2011 by Smart Money

UPDATE: FDA Declines Approval Of Protalix Gaucher's Drug Candidate

2/25/2011 by Smart Money

A Safe Strategy to Play Protalix

2/24/2011 by Seeking Alpha

4 Israeli Firms Headed to $1 Billion

2/23/2011 by Seeking Alpha

Conservative, Bullish Trading Strategy on Protalix Biotherapeutics' PDUFA Date

2/18/2011 by Seeking Alpha

UBS Analyst Misses Boat With Protalix Comments

2/14/2011 by Seeking Alpha

iBio: Risky, But Early Stage Pipeline Potentially Offers Long-Term Reward

2/11/2011 by Seeking Alpha

iBio Overvalued

2/9/2011 by Seeking Alpha

Maximizing Opportunity and Minimizing Risk With Trading FDA Decisions

2/8/2011 by Seeking Alpha

FDA Catalyst Trade: Protalix BioTherapeutics

2/2/2011 by Seeking Alpha

Insider Selling and Options Trading May Spell Troubles for Protalix

2/2/2011 by Seeking Alpha

iBio: A True Paradigm Shift

1/24/2011 by Seeking Alpha

Protalix BioTherapeutics: Recent Dip Represents Attractive Entry Point

1/20/2011 by Seeking Alpha
See More Articles...